TME Pharma's Ordinary Shares • Date of the IPO: September 28, 2016 *Taking into account the shares issuance following the exercise of Warrants Z as published on September 27, 2024.
TME Pharma's Warrants Z • ISIN NL0015001SR3
Rapid access to French brokers |
Aram Mangasarian, CEO: "We have received and taken note of the letter received from a shareholder group claiming 18% of TME shares referred to in the Boursier.com article of October 31st, 2024 (link). We thank the investors for thinking along with management and can confirm, as disclosed most recently in the 2024 half-year report, that management are actively pursuing multiple types of transactions for our lead asset, NOX-A12." Analyst Coverage
TME Pharma N.V. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding TME Pharma’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of TME Pharma or its management. TME Pharma does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
|
||||||||||
|